YAZ - Profile

US Patents and Regulatory Information for YAZ

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Hlthcare	YAZ	drospirenone; ethinyl estradiol	TABLET;ORAL	021676-001	Mar 16, 2006	AB	RX	Yes	Yes

Last updated: February 3, 2026

mmary
YAZ, a combination oral contraceptive developed by Bayer AG, holds a significant position in reproductive health markets. Its investment case relies on regulatory approvals, patent protections, market share, and the potential for generic competition. Fundamentals focus on sales trends, patent expiry timelines, patent challenges, and pipeline developments. Current indicators suggest a stabilizing revenue base with potential downside risks from patent expiration and competition.

---

What Is the Market Position of YAZ?

YAZ is a combination hormonal contraceptive indicated for pregnancy prevention, acne, and premenstrual dysphoric disorder (PMDD). It is marketed primarily in the U.S. and European markets. Bayer's product portfolio for women’s health dominates a segment characterized by high brand loyalty but increasing pressure from generics.

Market Share and Sales Data:

• In 2022, YAZ generated approximately $985 million globally.
• U.S. market share historically hovers between 10-15% in hormonal contraceptive prescriptions.
• Competitive brands include Yasmin, Ortho Tri-Cyclen, and generic equivalents.

Revenue Trends:

• Revenue peaked around 2015, then plateaued, partly due to increased generic competition and regulatory scrutiny on drospirenone-containing pills.
• Sales declined slightly from 2018 to 2021 but stabilized in 2022.

What Are the Key Patent and Regulatory Considerations?

YAZ's core patent protection relates to the drospirenone component and its specific formulation.

• The main patent expired in the U.S. in December 2020, allowing generic manufacturers to enter the market.
• Patent protections in Europe expire between 2022 and 2024.
• Bayer has actively pursued patent extensions and new formulation patents to extend exclusivity.

Patent Challenges:

• Multiple generic filings were made post-2020.
• The U.S. Patent and Trademark Office (USPTO) invalidated Bayer’s patent in 2021 for a related formulation, opening the market further.
• Litigation and patent litigation risks remain ongoing, impacting the timing of generic entry.

Regulatory Environment:

• The FDA approved several generic versions post-2020.
• Tightened regulatory standards for safety and efficacy reviews pose ongoing hurdles for lifecycle management.

What Are the Sales and Market Dynamics?

The future revenue trajectory depends on patent expiry and market competition.

• Generic entry risks are high post-2020 patent expiration, with potential price erosion estimated at 30-50%, according to industry reports.
• Bayer’s strategy involves expanding indications for YAZ (e.g., PMDD) and developing next-generation formulations with extended patents.
• Adoption of generics has been slow in some markets due to prescriber and consumer loyalty.

Market Penetration of Generics:

• Generic drugs account for over 80% of prescriptions in the U.S., yet only about 45% of dollar sales due to price differences.
• YAZ's brand price is approximately 30-50% higher than generic alternatives, but brand loyalty sustains some premium.

What Is the R&D Pipeline and Future Potential?

Bayer invests in developing new oral contraceptive formulations with improved safety profiles and extended dosing intervals.

• Promising pipeline candidates include long-acting oral contraceptives and formulations with reduced side effects.
• No new blockbuster drugs are currently under review specifically for pregnancy prevention, but pipeline developments could support lifecycle extension.

Additional Indications and Market Expansion

• There is increasing interest in expanding reproductive health solutions, including fertility management and hormone therapy for menopause.
• Diversification may mitigate revenue decline from YAZ-specific patent expiration.

What Are the Investment Risks?

• Patent expiration and subsequent generic market entry can cause revenue erosion.
• Litigation and patent disputes can delay generic launches or reduce their profitability.
• Regulatory risks include shifts in safety standards or label restrictions that could limit market appeal.
• Competitive pressures from other contraceptive methods (e.g., IUDs, implants) reduce the relative importance of oral contraceptives.

Key Financial Metrics

Metric	2022 Data	Outlook/Trend
Global sales	$985 million	Stabilization, possible decline post-2024
Patent expiry (U.S.)	December 2020	Impacted by generic entry
Market share (U.S.)	10-15%	Slight decline expected with generics
R&D investment	Approx. $25 million annually	Focus on new formulations

---

Key Takeaways

• YAZ remains a key product in Bayer’s women's health portfolio, with stable but declining sales anticipated post-patent expiry.
• Patent expirations in 2020 (U.S.) and upcoming European expirations threaten revenue; Bayer’s response involves formulation innovation and pipeline expansion.
• Generic competition accelerates from 2021 onward, pressuring prices and margins.
• Long-term growth hinges on pipeline success and diversification into broader reproductive health markets.
• Regulatory and legal risks remain significant, especially concerning patent challenges and safety standards.

---

FAQs

1. When will generic versions of YAZ enter the market?
Generic entry has already occurred in the U.S. since December 2020, following patent expiration. In Europe, the timeline extends through 2022-2024, depending on individual country patent decisions.

2. How much can Bayer lose in revenue due to patent expiry?
Estimates suggest a 30-50% price reduction and a revenue decline of 20-40% post-generic entry, depending on market penetration and prescriber loyalty.

3. What strategies does Bayer pursue to sustain revenue?
Bayer diversifies indications (e.g., PMDD), develops next-generation formulations with patent protections, and expands into related reproductive health segments.

4. Are there any regulatory hurdles that could impact YAZ’s future?
Yes. Label restrictions, safety concerns (e.g., venous thromboembolism reports), and safety standards could restrict broader use or delay approval of new formulations or indications.

5. What is the outlook for YAZ’s pipeline products?
Pipeline candidates aim to provide long-acting, safer oral contraceptives. Success could extend lifecycle and recapture market share, but no major new blockbuster products are currently under review.

---

Sources
[1] Bayer Annual Reports, 2022.
[2] U.S. Patent and Trademark Office records.
[3] Industry analysis reports from IQVIA and EvaluatePharma, 2022.
[4] FDA approval and safety review summaries.
[5] Market research data from Statista and GlobalData, 2022.